NASDAQ:TSRO

Tesaro Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

$74.96

0.00 (0.00 %)

(As of 01/18/2019)

Add

Compare

Today's Range

$74.94

▼

$74.97

50-Day Range N/A

52-Week Range

$23.41

▼

$75.16

Volume1.19 million shs

Average Volume1.97 million shs

Market Capitalization$4.13 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.38

Tesaro (NASDAQ:TSRO) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying TSRO stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Tesaro, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Tesaro vs. Amgen Stock

Tesaro (NASDAQ:TSRO) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Tesaro and Amgen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tesaro	0	0	0	0	N/A
Amgen	2	9	14	0	2.48

Amgen has a consensus price target of $255.6190, indicating a potential upside of 1.19%. Given Amgen's higher probable upside, analysts plainly believe Amgen is more favorable than Tesaro.

Insider & Institutional Ownership

75.2% of Amgen shares are held by institutional investors. 33.7% of Tesaro shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Tesaro and Amgen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tesaro	-295.67%	-1,209.72%	-83.34%
Amgen	29.42%	95.55%	15.52%

Risk & Volatility

Tesaro has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Earnings & Valuation

This table compares Tesaro and Amgen's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tesaro	$223.33 million	18.48	$-496,120,000.00	($9.17)	-8.17
Amgen	$23.36 billion	6.21	$7.84 billion	$14.82	17.05

Amgen has higher revenue and earnings than Tesaro. Tesaro is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Tesaro on 11 of the 13 factors compared between the two stocks.

Tesaro vs. Gilead Sciences Stock

Tesaro (NASDAQ:TSRO) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Tesaro and Gilead Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tesaro	0	0	0	0	N/A
Gilead Sciences	0	9	13	0	2.59

Gilead Sciences has a consensus price target of $99.7391, indicating a potential upside of 47.81%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Tesaro.

Insider & Institutional Ownership

76.4% of Gilead Sciences shares are held by institutional investors. 33.7% of Tesaro shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Tesaro and Gilead Sciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tesaro	-295.67%	-1,209.72%	-83.34%
Gilead Sciences	5.48%	37.77%	12.76%

Risk & Volatility

Tesaro has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Earnings & Valuation

This table compares Tesaro and Gilead Sciences' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tesaro	$223.33 million	18.48	$-496,120,000.00	($9.17)	-8.17
Gilead Sciences	$22.45 billion	3.78	$5.39 billion	$6.14	10.99

Gilead Sciences has higher revenue and earnings than Tesaro. Tesaro is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Tesaro on 11 of the 13 factors compared between the two stocks.

Tesaro vs. Vertex Pharmaceuticals Stock

Tesaro (NASDAQ:TSRO) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Tesaro and Vertex Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tesaro	0	0	0	0	N/A
Vertex Pharmaceuticals	0	4	16	1	2.86

Vertex Pharmaceuticals has a consensus price target of $293.4737, indicating a potential upside of 37.85%. Given Vertex Pharmaceuticals' higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Tesaro.

Insider & Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 33.7% of Tesaro shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Tesaro and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tesaro	-295.67%	-1,209.72%	-83.34%
Vertex Pharmaceuticals	38.51%	28.55%	20.68%

Risk & Volatility

Tesaro has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Earnings & Valuation

This table compares Tesaro and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tesaro	$223.33 million	18.48	$-496,120,000.00	($9.17)	-8.17
Vertex Pharmaceuticals	$4.16 billion	13.24	$1.18 billion	$4.29	49.63

Vertex Pharmaceuticals has higher revenue and earnings than Tesaro. Tesaro is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Tesaro on 12 of the 14 factors compared between the two stocks.

Tesaro vs. Regeneron Pharmaceuticals Stock

Tesaro (NASDAQ:TSRO) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Earnings & Valuation

This table compares Tesaro and Regeneron Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tesaro	$223.33 million	18.48	$-496,120,000.00	($9.17)	-8.17
Regeneron Pharmaceuticals	$7.86 billion	6.84	$2.12 billion	$21.47	23.40

Regeneron Pharmaceuticals has higher revenue and earnings than Tesaro. Tesaro is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tesaro has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Tesaro and Regeneron Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tesaro	0	0	0	0	N/A
Regeneron Pharmaceuticals	0	5	14	0	2.74

Regeneron Pharmaceuticals has a consensus price target of $656.3810, indicating a potential upside of 30.66%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Tesaro.

Profitability

This table compares Tesaro and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tesaro	-295.67%	-1,209.72%	-83.34%
Regeneron Pharmaceuticals	38.28%	28.97%	20.11%

Insider & Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 33.7% of Tesaro shares are held by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Tesaro on 10 of the 13 factors compared between the two stocks.

Tesaro vs. Biogen Stock

Tesaro (NASDAQ:TSRO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares Tesaro and Biogen's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tesaro	$223.33 million	18.48	$-496,120,000.00	($9.17)	-8.17
Biogen	$14.38 billion	2.89	$5.89 billion	$33.57	8.21

Biogen has higher revenue and earnings than Tesaro. Tesaro is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tesaro has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Tesaro and Biogen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tesaro	0	0	0	0	N/A
Biogen	4	14	12	0	2.27

Biogen has a consensus price target of $305.5714, indicating a potential upside of 10.87%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Tesaro.

Profitability

This table compares Tesaro and Biogen's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tesaro	-295.67%	-1,209.72%	-83.34%
Biogen	35.63%	51.00%	23.54%

Insider and Institutional Ownership

83.5% of Biogen shares are owned by institutional investors. 33.7% of Tesaro shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Biogen beats Tesaro on 11 of the 13 factors compared between the two stocks.

Tesaro vs. Alexion Pharmaceuticals Stock

Tesaro (NASDAQ:TSRO) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares Tesaro and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tesaro	$223.33 million	18.48	$-496,120,000.00	($9.17)	-8.17
Alexion Pharmaceuticals	$4.99 billion	7.61	$2.40 billion	$9.74	17.64

Alexion Pharmaceuticals has higher revenue and earnings than Tesaro. Tesaro is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Tesaro has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Tesaro and Alexion Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tesaro	0	0	0	0	N/A
Alexion Pharmaceuticals	0	15	4	0	2.21

Alexion Pharmaceuticals has a consensus price target of $159.3158, indicating a potential downside of 7.27%. Given Alexion Pharmaceuticals' higher probable upside, analysts plainly believe Alexion Pharmaceuticals is more favorable than Tesaro.

Profitability

This table compares Tesaro and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tesaro	-295.67%	-1,209.72%	-83.34%
Alexion Pharmaceuticals	16.32%	23.16%	14.76%

Insider and Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 33.7% of Tesaro shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Alexion Pharmaceuticals beats Tesaro on 11 of the 13 factors compared between the two stocks.